Filing Flows › Comparisons › COCP vs ACUT
Cocrystal Pharma vs Accustem Sciences: COCP and ACUT compared
Cocrystal Pharma is the larger company: $105K of revenue in its latest quarter (Q2 2026) against $98K for Accustem Sciences (Q2 2026).
Where the money goes: COCP and ACUT
Cocrystal Pharma (COCP) · Q2 2026
Cocrystal Pharma, Q2 2026: revenue $105K, net loss $3.2M, operating cash flow −$2.5M. The chart follows the revenue to costs, profit and cash.
Accustem Sciences (ACUT) · Q2 2026
Accustem Sciences, Q2 2026: revenue $98K, operating margin -256.7%, net loss $253K, operating cash flow −$249K. The chart follows the revenue to costs, profit and cash.
| Cocrystal Pharma (COCP) | Accustem Sciences (ACUT) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $105K | $98K |
| Operating margin | n/m | -256.7% |
| Net earnings | −$3.2M | −$253K |
| Net margin | — | -256.7% |
| Operating cash flow | −$2.5M | −$249K |
Questions
Which is bigger, Cocrystal Pharma or Accustem Sciences?
Cocrystal Pharma is the larger company: $105K of revenue in its latest quarter (Q2 2026) against $98K for Accustem Sciences (Q2 2026).
More: Cocrystal Pharma earnings · how Cocrystal Pharma makes money · Accustem Sciences earnings · how Accustem Sciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.